Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233481 | 1.00 | HRH3 (0.47) | HRH3CSF1RFLT3PKMSLC5A7 | |
| SCHEMBL4683501 | 0.96 | HRH3 (0.43) | HRH3CSF1RFLT3PKMSLC5A7 | |
| SCHEMBL4232082 | 0.93 | HRH3 (0.45) | HRH3CSF1RFLT3SLC5A7 | |
| SCHEMBL13699306 | 0.93 | SLC5A7 (0.44) | HRH3CSF1RFLT3PKMSLC5A7 | |
| SCHEMBL4743227 | 0.93 | HRH3 (0.40) | HRH3PKMSLC5A7POLB | |
| SCHEMBL4683606 | 0.91 | HRH3 (0.42) | HRH3CSF1RFLT3PKMSLC5A7 | |
| SCHEMBL4236845 | 0.91 | HRH3 (0.48) | HRH3CSF1RFLT3PKMSLC5A7 | |
| SCHEMBL4234320 | 0.91 | HRH3 (0.48) | HRH3PKMSLC5A7POLB | |
| SCHEMBL4233292 | 0.91 | HRH3 (0.48) | HRH3CSF1RFLT3PKMSLC5A7 | |
| SCHEMBL4237153 | 0.90 | HRH3 (0.48) | HRH3CSF1RFLT3PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885CSF1R 1368/4885FLT3 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.